{"id":125,"date":"2021-07-08T09:46:26","date_gmt":"2021-07-08T09:46:26","guid":{"rendered":"https:\/\/isosolution-v2.staging.xiyx.ai\/news\/https-isosolutions-com-wp-content-uploads-2021-07-psma-11-pet_ct-versus-choline-pet_ct-pdf\/"},"modified":"2026-09-04T19:48:39","modified_gmt":"2026-09-04T19:48:39","slug":"https-isosolutions-com-wp-content-uploads-2021-07-psma-11-pet_ct-versus-choline-pet_ct-pdf","status":"publish","type":"iso_news","link":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/news\/https-isosolutions-com-wp-content-uploads-2021-07-psma-11-pet_ct-versus-choline-pet_ct-pdf\/","title":{"rendered":"PSMA-11-PET\/CT versus choline-PET\/CT para guiar la radioterapia ablativa estereot\u00e1ctica para la terapia de privaci\u00f3n de andr\u00f3geno en pacientes con c\u00e1ncer de pr\u00f3stata oligometat\u00e1tico"},"content":{"rendered":"<p><strong>ABSTRACT<\/strong><\/p>\n<p>Antecedentes: En pacientes con c\u00e1ncer de pr\u00f3stata recidivante oligometat\u00e1tico, el tratamiento est\u00e1ndar es la terapia de privaci\u00f3n de andr\u00f3geno (ADT). Sin embargo, ADT tiene muchos efectos secundarios potenciales que pueden resultar en una calidad de vida deficiente. La identificaci\u00f3n temprana para seleccionar pacientes adecuados para la radioterapia ablativa estereot\u00e1ctica (SABR) es de suma importancia para prevenir o retrasar el inicio del ADT y sus efectos secundarios. <\/p>\n<\/p>\n<p>Debido a que Prostate-Specific Membrane Antigen-11- Positron Emission Tomography (PSMA-11-PET) tiene una mayor sensibilidad que el choline-PET, hip\u00f3tesis de que el SABR basado en PSMA-11-PET resulta en mayor duraci\u00f3n de la respuesta y posterior demora m\u00e1s larga en iniciar ADT que el choline-PET.<\/p>\n<p><strong>M\u00c9TODOS <\/strong><\/p>\n<p>Patients with oligometastatic (\u22644 metastases) recurrent prostate cancer (with no local recurrence) based on PSMA-11-PET or choline-PET treated with SABR from January 2012 until December 2017 were included. Primary endpoint was ADT-free survival. Secondary endpoints were Prostate Specific Antigen (PSA) response after SABR and time to PSA rise after SABR.<br \/>Resultados: Se incluyeron 50 pacientes (n = 40 PSMA-11-PET y n = 10 choline-PET) con 72 lesiones totales. El seguimiento medio fue de 24,3 meses. PSMA-11-PET permiti\u00f3 elegibilidad de pacientes con niveles inferiores de PSA que el choline-PET (mediana 1.8 versus 4.2 ng\/mL, p = 0.03). El grupo PSMA-11-PET tuvo una duraci\u00f3n de respuesta PSA significativa m\u00e1s larga (mediana 34.0 meses (95% intervalo de confianza (CI), 16.0\u201352.0) versus 14.7 meses (95% CI 4.7\u201324.7), p = 0.004) con una supervivencia posterior m\u00e1s larga libre de ADT (mediana 32,7 meses (95% CI, 20,8\u201344.5) versus 14.9 meses (951TP24T CI, 51).<\/p>\n<\/p>\n<p class=\"has-text-align-center\">\n<\/p>\n<p><strong>CONCLUSI\u00d3N<\/strong><\/p>\n<p>Con PSMA-11-PET podemos seleccionar pacientes con c\u00e1ncer de pr\u00f3stata recidivante oligometat\u00e1tico adecuado para SABR en un estadio de enfermedad anterior en niveles inferiores de PSA. PSMA-11-PET guiado SABR result\u00f3 en una duraci\u00f3n de respuesta m\u00e1s larga significativa y la supervivencia sin ADT en comparaci\u00f3n con el choline-PET y por lo tanto puede prevenir o retrasar efectos secundarios relacionados con ADT.<\/p>\n<p><a href=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" data-type=\"URL\"><\/a><a rel=\"noreferrer noopener\" href=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" data-type=\"URL\" data-id=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" target=\"_blank\">Leer <\/a><a href=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" data-type=\"URL\" data-id=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\">el <\/a><a rel=\"noreferrer noopener\" href=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" data-type=\"URL\" data-id=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" target=\"_blank\">completo <\/a><a href=\"https:\/\/isosolutions.com\/wp-content\/uploads\/2021\/07\/PSMA-11-PET_CT-versus-choline-PET_CT.pdf\" data-type=\"URL\" data-id=\"https:\/\/isosolutions.com\/wp-content\/uploads\/2021\/07\/PSMA-11-PET_CT-versus-choline-PET_CT.pdf\">art\u00edculo<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>ABSTRACT Background: In patients with oligometastatic recurrent prostate cancer, standard treatment is androgen deprivation therapy (ADT). However, ADT has many potential side effects that may result in impaired quality of life. Early identification to select patients suitable for stereotactic ablat<\/p>","protected":false},"featured_media":126,"template":"","iso_news_section":[43],"class_list":["post-125","iso_news","type-iso_news","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/iso_news\/125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/iso_news"}],"about":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/types\/iso_news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/media\/126"}],"wp:attachment":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/media?parent=125"}],"wp:term":[{"taxonomy":"iso_news_section","embeddable":true,"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/iso_news_section?post=125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}